Smith & Nephew SNATS

Smith & Nephew SNATS EBIT per Share

The EBIT per Share of Smith & Nephew SNATS (SNN) as of Nov 4, 2026 is 1.82 USD. In the previous year, EBIT per Share was 1.49 USD — a change of 21.79% (higher).

EBIT per Share

1.82USD

YoY

21.79%

Last updated:

EBIT per Share of Smith & Nephew SNATS is 2025 1.82 USD. EBIT per Share of Smith & Nephew SNATS was 2024 1.49 USD. It decreases by 21.79% higher compared to the previous year.

The Smith & Nephew SNATS EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
0.49 USD
Jan 1, 2024
1.49 USD
Jan 1, 2025
1.82 USD
Jan 1, 2026 (e)
2.83 USD
Jan 1, 2027 (e)
3.05 USD
Jan 1, 2028 (e)
3.37 USD
Jan 1, 2029 (e)
3.56 USD
Jan 1, 2030 (e)
3.73 USD
The Smith & Nephew SNATS EBIT per Share history
YEAREBIT per ShareYoY
est3.73USD+4.73%
est3.56USD+5.45%
est3.37USD+10.58%
est3.05USD+7.95%
est2.83USD+55.36%
1.82USD+21.79%
1.49USD+206.78%
0.49USD-5.90%
0.52USD-23.40%
0.68USD+101.59%
0.34USD-63.98%
0.93USD-5.82%
0.99USD-7.55%
1.07USD+18.71%
0.90USD+28.77%
0.70USD-15.78%
0.83USD-7.42%
0.90USD-4.65%
0.94USD-2.40%
0.96USD-6.93%
1.03USD+26.96%
0.82USD+14.76%
0.71USD+34.70%
0.53USD-7.31%
0.57USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS Stock analysis

What does Smith & Nephew SNATS do? Smith & Nephew SNATS Inc operates in the medical device sector, focusing on orthopaedic implants and surgical solutions. The company generates revenue through knee and hip implant products used in joint replacement procedures, including revision surgeries. Its trauma and extremities segment offers internal and external devices for fracture stabilization and deformity correction. Sports Medicine & ENT segment sells joint repair products, arthroscopic equipment, and tissue resection devices for minimally invasive surgeries. Advanced Wound Management provides specialized wound care solutions, though specific products are not detailed in the description. The primary buyers are healthcare providers and hospitals globally, particularly in the United Kingdom, United States, and international markets. Orthopaedics and Sports Medicine & ENT segments target surgeons and orthopaedic specialists, while Advanced Wound Management serves wound care professionals. The company’s products are sold under its own brand, with no external brand names mentioned in the description. Revenue streams include direct sales of medical devices to hospitals and clinics, with no mention of subscription models or service-based fees. The company’s focus on surgical solutions and implants drives its market position, with key segments defined by product categories rather than geographic regions. No additional revenue streams like data services or digital platforms are referenced in the business description. Smith & Nephew SNATS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Smith & Nephew SNATS stock

EBIT per Share of Smith & Nephew SNATS is 1.82 USD in 2025.

EBIT per Share of Smith & Nephew SNATS changed from 1.49 USD to 1.82 USD, representing a 21.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Smith & Nephew SNATS since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Smith & Nephew SNATS

All Key Metrics — Smith & Nephew SNATS